If you are diagnosed with advanced melanoma, testing the genetic characteristics of your tumour can help your specialist identify treatments designed for your particular type of cancer. One of the most important changes is a BRAF V600 mutation, which can make your melanoma suitable for targeted treatment.
The COMBI-d trial compared dabrafenib alone with dabrafenib plus trametinib in people with advanced BRAF V600-mutant melanoma. Its findings help you understand why BRAF and MEK inhibitors are commonly combined, what benefits the trial demonstrated and how targeted therapy fits into modern melanoma treatment.
What Was the COMBI-d Trial?
COMBI-d was an international, randomised, double-blind Phase III trial involving 423 people with previously untreated unresectable stage IIIC or stage IV melanoma containing a BRAF V600E or V600K mutation. If your melanoma carries one of these mutations, the trial provides important evidence about targeted treatment.
Participants received either dabrafenib plus trametinib or dabrafenib plus placebo. Researchers assessed whether blocking both BRAF and MEK could give you better disease control than blocking BRAF alone.
Why Was the COMBI-d Study Needed?
BRAF inhibitors had already shown that they could produce relatively rapid tumour responses in some people with BRAF-mutant melanoma. However, if your melanoma initially responded to BRAF inhibition, the benefit could decrease as cancer cells developed ways of restoring growth signals.
Researchers therefore investigated whether targeting two points within the same signalling pathway could delay progression and improve outcomes. COMBI-d helped establish whether adding trametinib to dabrafenib could provide you with more durable disease control.
What Is a BRAF V600 Mutation?
BRAF is part of a signalling pathway that helps control how your cells grow and divide. When your melanoma develops a BRAF V600 mutation, this pathway can remain abnormally active and continually encourage your melanoma cells to grow.
A substantial proportion of cutaneous melanomas contain an actionable BRAF V600 mutation. Testing your tumour is therefore important because your BRAF result can determine whether BRAF- and MEK-targeted medicines may be relevant to your treatment.
Why Does BRAF Testing Matter to You?
Targeted medicines need the appropriate molecular target to work as intended. If your melanoma does not contain a suitable BRAF mutation, dabrafenib and trametinib are unlikely to provide the targeted benefit for which they were developed.
Your BRAF result also gives your specialist more information when comparing targeted therapy with immunotherapy. Rather than determining your treatment by melanoma stage alone, molecular testing helps make your treatment more personalised.
What Side Effects Should You Know About?
Dabrafenib and trametinib can cause side effects even though they are targeted medicines. You may experience fever, tiredness, headache, skin symptoms, joint discomfort or gastrointestinal problems, although your individual experience can vary.
Some complications can be more serious and require treatment interruption or additional investigation. You should report significant new or worsening symptoms promptly so that your oncology team can assess whether they may be related to your treatment.
How Does Dabrafenib Work?
Dabrafenib is a BRAF inhibitor. If your melanoma contains an appropriate BRAF V600 mutation, dabrafenib blocks abnormal BRAF activity and interrupts signals that encourage your cancer cells to keep multiplying.
This can produce substantial tumour shrinkage in some people, but BRAF inhibition alone does not always maintain control indefinitely. Your melanoma may eventually restore signalling through the same pathway and become less responsive to treatment.
How Does Trametinib Work?
Trametinib is a MEK inhibitor that acts further along the MAPK signalling pathway. Blocking MEK reduces another signal that your BRAF-mutant melanoma can use to maintain cancer-cell growth.
When you receive trametinib with dabrafenib, two parts of the same pathway are blocked. This combined approach can produce better disease control than BRAF inhibition alone, although it cannot guarantee that your melanoma will never progress.
Why Are BRAF and MEK Inhibitors Combined?
If only BRAF is blocked, your melanoma cells can sometimes reactivate signalling further along the MAPK pathway. Adding a MEK inhibitor makes it more difficult for this pathway to continue driving tumour growth.
For you, the aim of combination treatment is to increase treatment effectiveness and delay disease progression. The COMBI-d results showed why dual BRAF–MEK inhibition became an important strategy for appropriate BRAF-mutant melanoma.
How Was the COMBI-d Trial Designed?
COMBI-d randomised 423 participants to dabrafenib plus trametinib or dabrafenib plus placebo. The study included people with previously untreated unresectable stage IIIC or stage IV melanoma carrying a confirmed BRAF V600E or V600K mutation.
The table below summarises several important COMBI-d findings. You should remember that these figures describe trial populations and cannot predict exactly what will happen with your own melanoma.
| Trial Feature | Dabrafenib + Trametinib | Dabrafenib Alone | What It Means for You |
| Participants | 211 | 212 | 423 people were randomised |
| Melanoma | BRAF V600E/K unresectable stage IIIC or stage IV | Same | Results apply to this trial population |
| Treatment | Dabrafenib 150 mg twice daily + trametinib 2 mg once daily | Dabrafenib 150 mg twice daily + placebo | The trial tested whether adding MEK inhibition improved outcomes |
| Primary endpoint | Progression-free survival | Progression-free survival | Researchers measured how long melanoma remained controlled |
| Initial median progression-free survival | 9.3 months | 8.8 months | The initial analysis favoured combination treatment |
| Updated median progression-free survival | About 11 months | 8.8 months | Longer follow-up continued to favour the combination |
| Initial objective response rate | About 67% | About 51% | Tumour responses were more frequent with combination treatment |
| Median overall survival | 25.1 months | 18.7 months | Later analysis demonstrated an overall-survival advantage |
What Did Progression-Free Survival Show?
The initial COMBI-d analysis reported median progression-free survival of 9.3 months with dabrafenib plus trametinib and 8.8 months with dabrafenib alone. Later follow-up reported a median of approximately 11 months for the combination while the dabrafenib-alone figure remained 8.8 months.
You should not interpret these medians as a timetable for your own disease. Your melanoma could remain controlled for a shorter or considerably longer period depending on your disease biology, overall health and response to treatment.
What Did Overall Survival Show?
Longer follow-up showed median overall survival of 25.1 months with dabrafenib plus trametinib compared with 18.7 months with dabrafenib alone. This demonstrated that the benefit of combination treatment extended beyond simply delaying progression.
These figures are averages across groups of trial participants rather than a prediction of your life expectancy. Your individual outcome may differ substantially, particularly because melanoma treatment options and treatment sequencing have continued to evolve since COMBI-d was conducted.
Research Insight
The COMBI-d findings are important because they demonstrated that blocking BRAF and MEK together could improve outcomes compared with BRAF inhibition alone. The study therefore provided direct randomised evidence supporting dual pathway inhibition in advanced BRAF V600-mutant melanoma.
You should also recognise what the study did not investigate. COMBI-d did not compare dabrafenib plus trametinib directly with modern first-line immunotherapy, so the trial cannot tell you that targeted treatment should automatically be selected before immunotherapy today.
How Is Targeted Therapy Used in Current UK Practice?
Dabrafenib plus trametinib remains a targeted treatment option for people with appropriate BRAF V600-mutant advanced melanoma. However, having a BRAF mutation does not automatically mean targeted therapy will be your first systemic treatment.
For untreated stage IV or unresectable stage III melanoma, current NICE guidance generally recommends immunotherapy when it is suitable. BRAF–MEK targeted treatment can be considered when immunotherapy options are contraindicated or when rapid disease progression makes rapid tumour control particularly important.
Did More People Experience Tumour Shrinkage?
The initial objective response rate was approximately 67% with dabrafenib plus trametinib compared with about 51% with dabrafenib alone. If your melanoma responds to targeted treatment, scans may show a measurable reduction in the size of your tumours.
A higher response rate does not mean everyone benefits or that every response lasts permanently. Your healthcare team will continue monitoring your scans, symptoms and general condition to establish how your melanoma is responding over time.
Does Combination Treatment Prevent Resistance?
No. Combination treatment can delay disease progression, but your melanoma can still develop resistance. Cancer cells can acquire or activate alternative mechanisms that allow growth to continue despite BRAF and MEK inhibition.
For you, the COMBI-d results are best understood as evidence that dual inhibition can improve and prolong disease control compared with BRAF inhibition alone. They should not be interpreted as evidence that treatment resistance has been permanently eliminated.
Why Is Fever Particularly Important?
Fever, or pyrexia, is one of the recognised side effects of dabrafenib plus trametinib. In some cases, your fever may be accompanied by chills, dehydration, low blood pressure or kidney problems and may require temporary interruption of treatment.
You should follow the specific instructions your oncology team gives you rather than continuing treatment or changing your doses independently when significant fever occurs. Your team also needs to consider infection and other possible causes of your symptoms.
Why Is Ongoing Monitoring Important?
Your healthcare team may monitor your general health, heart function, eyes, liver and other potential treatment-related problems depending on your individual risks and symptoms. Regular clinical review can help identify complications before they become more difficult to manage.
You should also tell your team about any other medicines you take and any important changes in your health. Close communication allows your treatment to be interrupted, adjusted or supported appropriately when necessary.
UK Guidance Note
Your treatment selection should take account of more than your BRAF mutation. Your oncology team may consider your general health, other medical conditions, disease burden, progression rate, brain metastases, expected treatment toxicity and ability to tolerate different therapies.
This means your BRAF result gives you an additional treatment option rather than dictating one automatic pathway. You and your specialist should consider why immunotherapy or targeted treatment is more appropriate for your particular clinical circumstances.
Why Might Rapid Disease Control Matter?
BRAF and MEK inhibitors can produce tumour responses relatively quickly in some people. If your melanoma is progressing rapidly or causing significant symptoms, your specialist may consider whether this potential for rapid disease control is clinically important for you.
Speed of response is not the only consideration. Your overall health, distribution of disease, brain involvement, previous treatments and the expected risks of each treatment strategy also influence the decision.
What If Your Melanoma Has Spread to the Brain?
Brain metastases can affect your treatment plan because your specialist needs to consider the number, size and symptoms of the metastases as well as whether you need corticosteroids. Surgery, stereotactic radiotherapy or other local treatment may also be appropriate for you.
You should not rely on COMBI-d alone to determine treatment for melanoma brain metastases. Your specialist will use additional evidence and multidisciplinary assessment to decide which systemic and local treatments are most suitable for your situation.
Clinical Tip
If your melanoma has a BRAF V600 mutation, ask your specialist why immunotherapy or targeted therapy is being recommended first for you. Understanding whether your disease speed, symptoms, tumour burden, brain involvement or other health factors are influencing the decision can make your treatment plan clearer.
You should also ask what symptoms need urgent reporting if you begin dabrafenib and trametinib. Knowing in advance how your team wants you to respond to fever or other new symptoms can help your treatment be managed safely.
Why Must Your Treatment Be Individualised?
Two people can both have advanced BRAF V600-mutant melanoma yet require different treatment strategies. Your disease burden, previous treatments, symptoms, other medical conditions and general fitness can all influence which approach is most suitable for you.
Your preferences matter as well. You should understand how your treatment is taken, how quickly it may work, which side effects may occur and what alternative options are available before you make a shared treatment decision.
What Could Future Melanoma Research Mean for You?
Researchers continue to investigate how best to sequence targeted therapy and immunotherapy and how resistance to BRAF–MEK treatment can be overcome. Better biomarkers may eventually help your specialist predict which approach is most likely to benefit you.
Future research may also identify new combinations or treatment strategies that provide longer disease control with fewer complications. This could make your melanoma care even more closely matched to the biology and behaviour of your tumour.
Evidence Note
COMBI-d provides strong randomised Phase III evidence that dabrafenib plus trametinib improved progression-free survival, response and overall survival compared with dabrafenib alone in previously untreated advanced BRAF V600E/K-mutant melanoma.
You should nevertheless recognise the study’s limits. COMBI-d did not compare targeted therapy with modern immunotherapy, did not show that resistance is permanently prevented and cannot predict how long your own melanoma will respond to treatment.
Myth vs Fact
| Myth | Fact |
| COMBI-d compared targeted therapy with immunotherapy | It compared dabrafenib plus trametinib with dabrafenib plus placebo |
| Every melanoma has a BRAF mutation | Only a proportion of melanomas carry an actionable BRAF V600 mutation |
| Everyone receiving the combination responded | The response rate was higher with the combination, but not every participant responded |
| Combination therapy prevents resistance permanently | It delayed progression, but resistance can still develop |
| Dabrafenib plus trametinib cures advanced melanoma | Prolonged disease control is possible, but cure cannot be guaranteed |
| A BRAF mutation automatically means targeted therapy comes first | Your current treatment choice also depends on suitability for immunotherapy and other clinical factors |
| COMBI-d established adjuvant treatment after surgery | Adjuvant dabrafenib plus trametinib was investigated in the separate COMBI-AD trial |
| The trial directly proved targeted therapy is better than immunotherapy | Immunotherapy was not a COMBI-d comparator |
| Targeted medicines only cause mild side effects | Important systemic complications can occur and require monitoring |
| You can stop follow-up once your melanoma shrinks | Your response and treatment-related effects still require continued specialist monitoring |
Key Takeaways
- COMBI-d showed that dabrafenib plus trametinib provided better disease control than dabrafenib alone in advanced BRAF V600-mutant melanoma.
- You should know that combination treatment can delay progression and improve survival, but it cannot guarantee permanent control or prevent resistance.
- Your BRAF result is important, but your specialist must also consider immunotherapy suitability, disease speed, symptoms, overall health and treatment risks.
- You should remain under specialist monitoring and report significant symptoms, particularly fever or other new problems, promptly during treatment.
Frequently Asked Questions
1. What was the COMBI-d trial?
COMBI-d was a randomised Phase III trial involving 423 people with previously untreated unresectable stage IIIC or stage IV BRAF V600E/K-mutant melanoma. It compared dabrafenib plus trametinib with dabrafenib alone to determine whether combined BRAF–MEK inhibition could improve your treatment outcomes.
2. What does a BRAF V600 mutation mean for you?
A BRAF V600 mutation causes abnormal signalling that encourages your melanoma cells to grow. If your tumour has an appropriate mutation, your specialist may consider BRAF- and MEK-targeted medicines among your treatment options.
3. How do dabrafenib and trametinib work?
Dabrafenib blocks abnormal BRAF activity while trametinib blocks MEK further along the same signalling pathway. Using both medicines can suppress the signals driving your melanoma more effectively than BRAF inhibition alone.
4. Did the combination improve progression-free survival?
Yes. COMBI-d showed longer progression-free survival with dabrafenib plus trametinib than with dabrafenib alone. You should view the reported median figures as group averages rather than a prediction of how long your melanoma will remain controlled.
5. Did the combination improve overall survival?
Yes. Later follow-up reported median overall survival of 25.1 months with combination treatment compared with 18.7 months with dabrafenib alone. Your personal outcome may be shorter or considerably longer than either trial median.
6. Can dabrafenib plus trametinib cure your melanoma?
The treatment can produce substantial and sometimes prolonged disease control, but it cannot guarantee a permanent cure for advanced melanoma. Your melanoma can eventually become resistant, so continued specialist monitoring remains important.
7. Why should you report fever during treatment?
Fever is a recognised side effect of dabrafenib plus trametinib and can sometimes be associated with dehydration, low blood pressure or kidney complications. You should contact your treatment team and follow their individual instructions if significant fever develops.
8. Will targeted therapy always be used before immunotherapy?
No. Current UK treatment decisions usually consider immunotherapy first when it is suitable for untreated advanced melanoma. Your specialist may consider targeted treatment when immunotherapy is unsuitable or when your melanoma requires particularly rapid disease control.
9. Why do you need BRAF testing?
Your healthcare team needs to confirm that your melanoma contains an appropriate BRAF mutation before using these targeted medicines. The test helps ensure your treatment is matched to the molecular characteristics of your tumour.
10. Why do you still need follow-up during targeted therapy?
Your specialist needs to assess whether your melanoma remains controlled and whether your treatment is causing important side effects. Regular follow-up also gives you an opportunity to report symptoms and discuss whether your current treatment remains appropriate.
Final Thoughts: What Does the COMBI-d Trial Mean for You?
The COMBI-d trial helped establish combined BRAF and MEK inhibition as an important treatment strategy for advanced BRAF V600-mutant melanoma by demonstrating better disease control and survival than BRAF inhibition alone. Your treatment decision today should still reflect current UK guidance, the characteristics of your melanoma and your individual balance of potential benefit and risk.
If you’d like to book a consultation with a dermatologist in London, you can contact us at the London Dermatology Centre.
References:
- Long, G.V., Stroyakovskiy, D., Gogas, H. et al. (2014) ‘Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma’, New England Journal of Medicine, 371(20), pp. 1877–1888. Available at: https://pubmed.ncbi.nlm.nih.gov/25265492/
- Long, G.V., Stroyakovskiy, D., Gogas, H. et al. (2015) ‘Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial’, The Lancet, 386(9992), pp. 444–451. Available at: https://pubmed.ncbi.nlm.nih.gov/26037941/
- Long, G.V., Eroglu, Z., Infante, J. et al. (2017) ‘Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib’, Journal of Clinical Oncology. Available at: https://pubmed.ncbi.nlm.nih.gov/28475671/
- NICE (2022) ‘Melanoma: assessment and management (NG14)’. Available at: https://www.nice.org.uk/guidance/ng14/chapter/recommendations
- NICE ‘Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma’. Available at: https://www.nice.org.uk/guidance/ta321
- Electronic Medicines Compendium (2026) ‘Tafinlar 75 mg hard capsules – Summary of Product Characteristics’. Available at: https://www.medicines.org.uk/emc/product/7837/smpc
- Electronic Medicines Compendium (2026) ‘Mekinist 0.5 mg film-coated tablets – Summary of Product Characteristics’. Available at: https://www.medicines.org.uk/emc/product/7792/smpc